Skip to main content
. 2019 Mar 24;10(3):136–148. doi: 10.5306/wjco.v10.i3.136

Figure 3.

Figure 3

Estimated survival function of head and neck squamous cell carcinoma patients for fibroblast growth factor receptor 4 genotype and expression. A: Wildtype fibroblast growth factor receptor 4 (FGFR4) Gly388 and mutant FGFR4 Arg388 are compared. The P-value reported is the result of the Log-rank test for comparison of survivals; B: Weak expression vs high expression are shown within the first 24 mo of survival study.